FBXO45 is significantly overexpressed in T2E-positive PCA and is also associated with an unfavourable clinical course only in this subgroup, which further supports the subtype-specific consideration, especially concerning TMRPSS2–ERG fusion, in the development of robust prognostic biomarker models for PCA. Here, FBXO45 is linked to posterior cortical atrophy.